Solventum Co. (NYSE:SOLV) Given Consensus Rating of "Hold" by Brokerages

Shares of Solventum Co. (NYSE:SOLV - Get Free Report) have received an average recommendation of "Hold" from the eleven analysts that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation and two have given a buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $80.29.

SOLV has been the subject of several research analyst reports. The Goldman Sachs Group boosted their price objective on shares of Solventum from $63.00 to $71.00 and gave the company a "sell" rating in a research report on Monday, March 3rd. Wells Fargo & Company boosted their price objective on shares of Solventum from $73.00 to $75.00 and gave the company an "equal weight" rating in a research report on Friday, February 28th. Morgan Stanley boosted their price objective on shares of Solventum from $73.00 to $80.00 and gave the company an "equal weight" rating in a research report on Wednesday, March 5th. KeyCorp initiated coverage on shares of Solventum in a research report on Friday. They set a "sector weight" rating for the company. Finally, Mizuho boosted their price objective on shares of Solventum from $70.00 to $82.00 and gave the company a "neutral" rating in a research report on Monday, March 3rd.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Vanguard Group Inc. raised its position in Solventum by 0.5% during the 4th quarter. Vanguard Group Inc. now owns 16,266,893 shares of the company's stock worth $1,074,591,000 after purchasing an additional 75,631 shares during the last quarter. Trian Fund Management L.P. raised its position in Solventum by 18.8% during the 4th quarter. Trian Fund Management L.P. now owns 8,462,819 shares of the company's stock worth $559,054,000 after purchasing an additional 1,336,564 shares during the last quarter. Independent Franchise Partners LLP grew its holdings in Solventum by 263.1% during the 1st quarter. Independent Franchise Partners LLP now owns 5,820,724 shares of the company's stock worth $442,608,000 after acquiring an additional 4,217,570 shares during the period. Davis Selected Advisers grew its holdings in Solventum by 0.8% during the 1st quarter. Davis Selected Advisers now owns 5,288,138 shares of the company's stock worth $402,110,000 after acquiring an additional 41,524 shares during the period. Finally, Geode Capital Management LLC grew its holdings in Solventum by 3.4% during the 4th quarter. Geode Capital Management LLC now owns 3,460,405 shares of the company's stock worth $227,992,000 after acquiring an additional 112,686 shares during the period.

Solventum Trading Down 0.7%

Shares of SOLV stock opened at $74.83 on Monday. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45. The stock has a market cap of $12.95 billion, a P/E ratio of 34.64, a price-to-earnings-growth ratio of 1.94 and a beta of 0.54. The stock has a 50 day simple moving average of $69.36 and a 200 day simple moving average of $71.55. Solventum has a 1 year low of $47.16 and a 1 year high of $85.92.

Solventum (NYSE:SOLV - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.19 by $0.15. The company had revenue of $2.07 billion during the quarter, compared to the consensus estimate of $2.02 billion. The company's quarterly revenue was up 2.7% on a year-over-year basis. During the same quarter last year, the firm posted $2.08 earnings per share. On average, research analysts predict that Solventum will post 6.58 earnings per share for the current fiscal year.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.